Changing Treatment Landscape of Hepatocellular Carcinoma: A Real-World Retrospective Analysis of Treatment Algorithms and Outcomes of Patients over 10 Years.
Ten-year real-world data quantify survival gains from immunotherapy combinations, contextualizing modern hepatocellular carcinoma progress.
This 10-year retrospective analysis captures the full evolution of hepatocellular carcinoma treatment algorithms, from sorafenib-era through the current immunotherapy-combination era, with real-world survival data. The longitudinal perspective provides context for interpreting the magnitude of survival benefit achieved with immuno-oncology regimens compared to prior standards.
What the study was
- Study design
- Retrospective real-world cohort over 10 years
- Population
- Hepatocellular carcinoma patients treated over 10 years at a single German center
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Targeted oncology
Why it surfaced
10-year HCC treatment evolution including immunotherapy era provides valuable longitudinal benchmarking data. Directly relevant to novel therapeutics watchlist. Published in Targeted Oncology.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.